ProfileGDS4814 / ILMN_2307407
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 26% 20% 27% 39% 38% 40% 36% 56% 41% 52% 32% 50% 12% 24% 11% 35% 53% 28% 48% 53% 48% 32% 55% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)44.719126
GSM780708Untreated after 4 days (C2_1)43.636220
GSM780709Untreated after 4 days (C3_1)45.072327
GSM780719Untreated after 4 days (C1_2)47.566239
GSM780720Untreated after 4 days (C2_2)47.305938
GSM780721Untreated after 4 days (C3_2)47.735240
GSM780710Trastuzumab treated after 4 days (T1_1)46.806936
GSM780711Trastuzumab treated after 4 days (T2_1)52.773156
GSM780712Trastuzumab treated after 4 days (T3_1)47.874741
GSM780722Trastuzumab treated after 4 days (T1_2)51.212452
GSM780723Trastuzumab treated after 4 days (T2_2)45.93132
GSM780724Trastuzumab treated after 4 days (T3_2)50.346150
GSM780713Pertuzumab treated after 4 days (P1_1)41.679712
GSM780714Pertuzumab treated after 4 days (P2_1)44.393624
GSM780715Pertuzumab treated after 4 days (P3_1)41.426211
GSM780725Pertuzumab treated after 4 days (P1_2)46.669335
GSM780726Pertuzumab treated after 4 days (P2_2)51.720453
GSM780727Pertuzumab treated after 4 days (P3_2)45.179328
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)49.763348
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)51.665953
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)49.707648
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)46.001632
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)52.31755